ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 578,08
-0,72%
Dow Jones
40 211,72
0,00%
DAX
18 499,97
-0,54%
Brent Oil
83,045
-1,54%
Bitcoin
63 946,77
-1,40%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PureTech Health PLC (PRTC)

  7. PureTech Health PLC (PRTC) Actualités

PRTC

PureTech Health (PRTC)

PureTech Health PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRTC
DateHeureSourceTitreSymboleSociété
03/01/202413h00Business WirePureTech to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
22/12/202315h13Business WirePureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 BillionNASDAQ:PRTCPureTech Health PLC
20/12/202308h00Business WirePureTech Year End Update and Outlook for 2024NASDAQ:PRTCPureTech Health PLC
07/12/202312h00Business WirePureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023NASDAQ:PRTCPureTech Health PLC
29/11/202316h17Business WirePureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:PRTCPureTech Health PLC
17/11/202308h00Business WirePureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaNASDAQ:PRTCPureTech Health PLC
14/11/202308h00Business WirePureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy VolunteersNASDAQ:PRTCPureTech Health PLC
02/11/202321h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
17/10/202308h00Business WirePureTech to Present at Two Upcoming Investor ConferencesNASDAQ:PRTCPureTech Health PLC
11/10/202313h00Business WirePureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual MeetingNASDAQ:PRTCPureTech Health PLC
04/10/202313h05Business WirePureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track DesignationNASDAQ:PRTCPureTech Health PLC
28/09/202313h38Business WireKarXT, invented at PureTech, submitted for FDA Approval in SchizophreniaNASDAQ:PRTCPureTech Health PLC
27/09/202308h05Business WirePureTech Announces the Appointment of Robert Lyne as Chief Portfolio OfficerNASDAQ:PRTCPureTech Health PLC
29/08/202308h00Business WirePureTech Health plc – Half-Year ReportNASDAQ:PRTCPureTech Health PLC
22/08/202308h00Business WirePureTech Health: Notice of Half-Yearly ResultsNASDAQ:PRTCPureTech Health PLC
01/08/202313h00Business WirePureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia SyndromeNASDAQ:PRTCPureTech Health PLC
21/06/202313h00Business WirePureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety DisordersNASDAQ:PRTCPureTech Health PLC
13/06/202318h40Business WireResults of PureTech's Annual General MeetingNASDAQ:PRTCPureTech Health PLC
12/06/202322h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRTCPureTech Health PLC
24/05/202313h00Business Wire PureTech to Present at the Jefferies Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
09/05/202308h00Business WirePureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease WeekNASDAQ:PRTCPureTech Health PLC
04/05/202308h00Business WirePureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based TherapeuticNASDAQ:PRTCPureTech Health PLC
28/04/202313h29Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PRTCPureTech Health PLC
28/04/202308h00Business WirePureTech Announces Annual Results for Year Ended December 31, 2022NASDAQ:PRTCPureTech Health PLC
25/04/202312h50Business WirePureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia TherapiesNASDAQ:PRTCPureTech Health PLC
17/04/202313h05Business WirePureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMIDNASDAQ:PRTCPureTech Health PLC
13/04/202308h00Business WirePureTech Health: Notice of ResultsNASDAQ:PRTCPureTech Health PLC
23/03/202312h00GlobeNewswire Inc.Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 MillionNASDAQ:PRTCPureTech Health PLC
23/03/202308h00Business WirePureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 MillionNASDAQ:PRTCPureTech Health PLC
01/03/202313h00Business WirePureTech to Present at the Barclays Global Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
 Showing the most relevant articles for your search:NASDAQ:PRTC

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
HO
Thales
NYSE
MCD
McDonalds
EU
ACA
Credit Agricole
EU
RI
Pernod Ricard
NYSE
NKE
Nike
EU
BNP
BNP Paribas
EU
PX4
SBF 120
EU
CAP
Capgemini
NASDAQ
NVDA
NVIDIA
EU
RNO
Renault
NYSE
KO
Coca Cola
EU
BEL20
Bel 20
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés